IMPEDIMED LIMITED — Director's Dealing 2022

Jan 5, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited ABN: 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robert Graham
Date of last notice	08 October 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	RM Graham Pty Ltd
(including registered holder)	Astrusteefor	R&J	Graham	Family
Note: Provide details of the circumstances	Superannuation Fund
giving rise to the relevant interest.
	Dr Graham is a director of		RM Graham Pty
	Ltd and a beneficiary of the Superannuation
	Fund.
Date of change	04 January 2022
No. of securities held prior to change	Direct:
	1,136,121 Ordinary	shares
	Indirect:
	773,186 Ordinary shares
Class	Ordinary shares
Number acquired	Direct:
	59,911 Ordinary shares

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/Consideration	$0.169 per share
Note: If consideration is non-cash, provide
details and estimated valuation
No. of securities held after change	Direct:
	1,196,032 Ordinary shares
	Indirect:
	773,186 Ordinary shares
Nature of change	Issue of shares in lieu of 60% of director fees
Example: on-market trade, off-market trade,	for quarter ended 31 December 2021.
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?
If prior written clearance was provided, on what date wasthis provided?

Date of Notice:06 January 2022

• See chapter 19 for defined terms.

Appendix 3Y Page 2